Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops
automatic filling
dry powder inhaler
high dose pulmonary delivery
inhalation
tuberculosis
vacuum drum filler
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
09 Jul 2020
09 Jul 2020
Historique:
received:
13
06
2020
revised:
07
07
2020
accepted:
08
07
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
15
7
2020
Statut:
epublish
Résumé
In recent years there has been increasing interest in the pulmonary delivery of high dose dry powder drugs, such as antibiotics. Drugs in this class need to be dosed in doses far over 2.5 mg, and the use of excipients should therefore be minimized. To our knowledge, the effect of the automatic filling of high dose drug formulations on the maximum dose that can be filled in powder inhalers, and on the dispersion behavior of the powder, have not been described so far. In this study, we aimed to investigate these effects after filling with an Omnidose, a vacuum drum filler. Furthermore, the precision and accuracy of the filling process were investigated. Two formulations were used-an isoniazid formulation we reported previously and an amikacin formulation. Both formulations could be precisely and accurately dosed in a vacuum pressure range of 200 to 600 mbar. No change in dispersion was seen after automatic filling. Retention was decreased, with an optimum vacuum pressure range found from 400 to 600 mbar. The nominal dose for amikacin was 57 mg, which resulted in a fine particle dose of 47.26 ± 1.72 mg. The nominal dose for isoniazid could be increased to 150 mg, resulting in a fine particle dose of 107.35 ± 13.52 mg. These findings may contribute to the understanding of the upscaling of high dose dry powder inhalation products.
Identifiants
pubmed: 32659899
pii: pharmaceutics12070645
doi: 10.3390/pharmaceutics12070645
pmc: PMC7407802
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmaceutics. 2019 May 13;11(5):
pubmed: 31086107
Pharmaceutics. 2019 Dec 25;12(1):
pubmed: 31881695
Eur J Pharm Biopharm. 2015 Feb;90:8-15
pubmed: 25615881
Br J Clin Pharmacol. 2003 Dec;56(6):588-99
pubmed: 14616418
Int J Pharm. 2014 Oct 1;473(1-2):617-26
pubmed: 25087508
Pharm Res. 2008 May;25(5):999-1022
pubmed: 18040761
Curr Pharm Des. 2015;21(40):5900-14
pubmed: 26446471
AAPS PharmSciTech. 2017 Jul;18(5):1843-1854
pubmed: 27844415
Int J Pharm. 2014 Aug 25;471(1-2):182-8
pubmed: 24836668
Int J Pharm. 2018 Sep 5;548(1):325-336
pubmed: 29991452
Int J Pharm. 2013 Sep 15;454(1):381-7
pubmed: 23872302
Int J Pharm. 2001 Oct 4;227(1-2):5-26
pubmed: 11669069
Int J Pharm. 2012 Apr 4;425(1-2):73-4
pubmed: 22266530
Adv Drug Deliv Rev. 2014 Aug;75:18-31
pubmed: 24735675
Ther Deliv. 2010 Jul;1(1):195-201
pubmed: 22816126
Int J Pharm. 2017 Jan 10;516(1-2):9-20
pubmed: 27826028
Pharm Res. 2012 Oct;29(10):2926-35
pubmed: 22695732